Parkinson's disease and RLS: the dopaminergic bridge

被引:74
|
作者
Rye, DB [1 ]
机构
[1] Emory Univ, Sch Med, Program Sleep Med, Atlanta, GA 30322 USA
关键词
restless legs syndrome; dopamine; Parkinson's disease;
D O I
10.1016/j.sleep.2004.01.016
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Dopamine is a neurotransmitter that modulates diverse waking behaviors including movement, motivation, cognition, reward, and feeding Interest in dopamine's additional contributions to normal and pathologic sleep-wake states has experienced a recent rebirth originating from two clinical disorders: Parkinson's disease and Restless Legs Syndrome. The former, the prototypical disorder of brain dopamine cell loss, is accompanied by marked sleep disruption and impairments in daytime alertness. The latter is exquisitively responsive to pharmacologic agents that act upon dopamine receptors. The potential neurobiological substrates underlying these observations are reviewed here. Converging lines of evidence suggest that mesocorticolimbic dopamine circuits are involved in promoting wakefulness, while a less studied diencephalospinal dopamine system might underly the sensorimotor dysfunction of Restless Legs Syndrome. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:317 / 328
页数:12
相关论文
共 50 条
  • [31] Striatal dopaminergic denervation and hypomimia in Parkinson's disease
    Pasquini, J.
    Pavese, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (01) : E2 - E3
  • [32] The genetics of Parkinson's Disease and the loss of dopaminergic neurons
    Schalkamp, Ann-Kathrin
    Sandor, Cynthia
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2023, 31 : 698 - 698
  • [33] Determinants of dopaminergic neuron loss in Parkinson's disease
    Surmeier, Dalton James
    FEBS JOURNAL, 2018, 285 (19) : 3657 - 3668
  • [34] Dopaminergic modulation of the praxis network in Parkinson's disease
    Matt, Eva
    Fischmeister, Florian Ph. S.
    Foki, Thomas
    Beisteiner, Roland
    NEUROIMAGE-CLINICAL, 2019, 24
  • [35] Anxiety and dopaminergic stimulation in patients with Parkinson's disease
    Camacho Nieto, A.
    Franco Salinas, A. R.
    Ruiz-Escribano Menchen, L.
    Gallardo Alcaniz, M. J.
    Cabello Rosa, J. P.
    Vaamonde Gamo, J.
    MOVEMENT DISORDERS, 2019, 34 : S627 - S627
  • [36] THE ROLE OF DOPAMINERGIC THERAPY ON COGNITION IN PARKINSON'S DISEASE
    Kouhsari, L. Montaser
    Bakkour, A.
    Shohamy, D.
    PARKINSONISM & RELATED DISORDERS, 2023, 113 : 25 - 25
  • [37] Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease
    Isaias, Ioannis U.
    Trujillo, Paula
    Summers, Paul
    Marotta, Giorgio
    Mainardi, Luca
    Pezzoli, Gianni
    Zecca, Luigi
    Costa, Antonella
    FRONTIERS IN AGING NEUROSCIENCE, 2016, 8
  • [38] Implications of dopaminergic medication withdrawal in Parkinson's disease
    Koschel, J.
    Chaudhuri, K. Ray
    Toenges, L.
    Thiel, M.
    Raeder, V
    Jost, W. H.
    JOURNAL OF NEURAL TRANSMISSION, 2022, 129 (09) : 1169 - 1178
  • [39] Dopaminergic Axons: Key Recitalists in Parkinson’s Disease
    Abhishek Kumar Mishra
    Anubhuti Dixit
    Neurochemical Research, 2022, 47 : 234 - 248
  • [40] Dopaminergic agonists in the treatment of Parkinson's disease: A review
    Piccoli, F
    Riuggeri, RM
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1995, (45): : 187 - 195